Cilazapril unplugged – what alternatives?

Contributor
He Ako Hiringa
19 July 2021
Bulletin #5

Cilazapril - going, going, gone

Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2

Read the HAH Bulletin to find out more.

References

  1. Pharmac Cilazapril: No new patients from 1 May 2021. 10 May 2020. https://pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/cilazapril/
  2. BPACnz. Prescribing ACE inhibitors: time to reconsider old habits. March 2021. https://bpac.org.nz/2021/ace.aspx
  3. BPACnz. Slowing progression of renal dysfunction in patients with diabetes. June 2019. https://bpac.org.nz/2019/renal.aspx
  4. Li ECK, Heran BS, Wright JM. Angiotensin converting enzyme (ACE) inhibitor versus angiotensin receptor blockers for primary hypertension. Cochrane Database of Systematic Reviews 2014:CD009096.pub2.